BICO Group AB (publ)の最新の1株当たり利益は$-1.86で、$-1.02の予想を打ちつける。
BICO Group AB (publ) CLLKFの前四半期の収益はどうでしたか?
BICO Group AB (publ)の前四半期の収益は$-1.86です。
BICO Group AB (publ)の収益見積もりはいくらですか?
5人のウォール街のアナリストによると、BICO Group AB (publ)の収益見積もりは$406.35Mから$374.36Mの範囲です。
BICO Group AB (publ)の収益品質スコアはどれくらいですか?
BICO Group AB (publ)の収益品質スコアは/です。このスコアは、収益性、成長、キャッシュ生成と資本配分、レバレッジの4つの次元に基づいています。
BICO Group AB (publ)はいつ収益を報告しますか?
BICO Group AB (publ)の次の収益報告は2026-07-29に予定されています
BICO Group AB (publ)の予想収益はいくらですか?
ウォール街のアナリストによると、BICO Group AB (publ)の予想収益は$334.86Mです。
BICO Group AB (publ)は収益予想を上回りましたか?
BICO Group AB (publ)の最近の収益は$329.9Mで、予想を打ち勝たない。
主要データ
前終値
$1.53
始値
$1.53
当日レンジ
$1.53 - $1.53
52週レンジ
$1.52 - $3.75
取引高
600
平均取引高
2.9K
配当利回り
--
1株当たり利益(TTM)
-2.15
時価総額
$105.6M
BICO GROUP ABとは何ですか?
BICO Group AB engages in the provision of technologies, products, and services to create, understand, and master biology. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 589 full-time employees. The company went IPO on 2016-11-03. The firm focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The firm develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.